EUVIMEDEUVIMED entdecken
Crossref

Role of Phacoemulsification in Primary Angle-Closure Disease after Patent Peripheral Iridotomy: A Prospective Study

Paridhi Gupta, Ravi Soni, Meemansha Maheshwari, M.K. Taneja

International Journal of Current Pharmaceutical Review and Research · 30.04.2026 · 18 (04)

DOI: 10.25258/ijcpr.18.4.169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.04.2026. Verfasst von Paridhi Gupta und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary angle-closure disease remains an important cause of glaucomatous visual loss. Although laser peripheral iridotomy is the standard initial treatment, raised intraocular pressure and persistent angle crowding may continue after a patent iridotomy. Lens extraction has therefore emerged as a potential therapeutic strategy in selected eyes with coexisting cataract.

Methods

This prospective study included 48 eyes of 48 patients with primary angle closure (PAC, n=18) or primary angle-closure glaucoma (PACG, n=30), patent peripheral iridotomy, visually significant cataract, and raised intraocular pressure on topical antiglaucoma medication. All eyes underwent phacoemulsification through a temporal incision. Preoperative assessment included applanation tonometry, gonioscopy, A-scan biometry, and anterior segment optical coherence tomography. Patients were followed for 12 months. Outcomes included intraocular pressure, anterior chamber angle width, visual acuity, and antiglaucoma medication use.

Results

Mean preoperative intraocular pressure was 35.5 ± 4.8 mmHg and decreased to 14.6 ± 3.5 mmHg at 12 months, corresponding to a 58.9% reduction. Mean anterior chamber angle width increased from 16.4 ± 3.0° preoperatively to 29.0 ± 3.9° at 12 months, a 76.2% increase. The proportion classified under improved visual acuity increased from 4 eyes (8.33%) preoperatively to 42 eyes (87.5%) postoperatively. Antiglaucoma medication use decreased from 47 eyes (97.92%) preoperatively to 2 eyes (4.17%) postoperatively (p < 0.001).

Conclusion

Phacoemulsification was associated with sustained intraocular pressure reduction, marked widening of the anterior chamber angle, improved visual acuity, and substantially reduced dependence on antiglaucoma medication in eyes with primary angle-closure disease after patent peripheral iridotomy.

Zitieren

APA

Gupta, P., Soni, R., Maheshwari, M., & Taneja, M. (2026). Role of Phacoemulsification in Primary Angle-Closure Disease after Patent Peripheral Iridotomy: A Prospective Study. International Journal of Current Pharmaceutical Review and Research, 18(04). https://doi.org/10.25258/ijcpr.18.4.169

Vancouver

Gupta P, Soni R, Maheshwari M, Taneja M. Role of Phacoemulsification in Primary Angle-Closure Disease after Patent Peripheral Iridotomy: A Prospective Study. International Journal of Current Pharmaceutical Review and Research. 2026;18(04). doi:10.25258/ijcpr.18.4.169

BibTeX
@article{Gupta2026,
  author = {Gupta, Paridhi and Soni, Ravi and Maheshwari, Meemansha and Taneja, M.K.},
  title = {Role of Phacoemulsification in Primary Angle-Closure Disease after Patent Peripheral Iridotomy: A Prospective Study},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {04},
  doi = {10.25258/ijcpr.18.4.169}
}
Kostenlos starten →